Downloads

  1. Protein Degraders: From Discovery To Development 3/17/2026

    Leverage integrated platforms for targeted protein degradation and molecular glue solutions, from ligand identification to IND-enabling studies. Advanced screening and structural biology support accelerate discovery.

  2. Pipetting Robot For Full Workflow Automation 3/16/2026

    Frees you from routine pipetting and provides excellent results

  3. Streamlining Magnetic Bead Purifications 3/16/2026

    We have introduced the MAG and HEATMAG modules with you, the scientists, in mind.

  4. Magnetic Beads For NGS Size Selection And PCR Purification 3/16/2026

    MAGFLO magnetic beads are only available in Austria, Belgium, Denmark, France, Germany, Ireland, Netherlands, Sweden, Switzerland and the United Kingdom.

  5. What Matters More In DNA-Encoded Libraries? 3/16/2026

    DELs can screen billions of compounds, but library quality determines meaningful results. See how thoughtful design shapes early decisions that influence which drug candidates move forward.

  6. Proteomics Biomarkers Beyond Blood 3/16/2026

    Effective biomarker strategies have the potential to accelerate decision-making, de-risk development, and help drive precision medicine.

  7. MicroRNA Therapeutics In Metabolic Liver Disease: Context-Driven Drug Discovery 3/12/2026

    Realizing the therapeutic potential of miRNAs in liver disease requires confronting a problem the field has not fully reckoned with.

  8. Viral Coinfections: Emerging Challenges In Modern Drug Discovery 3/11/2026

    Viral coinfection is a phenomenon more complex than just the concurrency or sequential infection with multiple viruses in the same host. 

  9. Execution Debt In Early Drug Discovery: The Hidden Risk That Undermines Promising Biology 3/10/2026

    Understanding how execution debt forms, how it compounds, and how to prevent it is central to building durable discovery programs.

  10. Hope For Non-Hallucinogenic Neuroplastogens 3/9/2026

    We caught up with Joseph Tucker, Ph.D., to discuss Enveric Bioscience’s focus on developing non-hallucinogenic neuroplastogenic compounds.